A scientificity and feasibility evaluation of COVID-19 clinical studies registered in China

Abstract

BACKGROUND: An outbreak of novel coronavirus infection in Wuhan, China, in early 2020 has now developed into a worldwide pandemic. Researchers in China and around the world have conducted many clinical studies on the scientific response to infectious diseases. Here, we review and summarize the registration protocols for clinical research of the novel coronavirus disease (COVID-19). METHODS: We searched all the registered studies in all platforms under the International Clinical Trials Registry Platform (ICTRP) of the World Health Organization (WHO) before March 11, 2020, screened the registration scheme for novel coronavirus, extracted the basic research information, research quality, feasibility information, and described the scientificity and feasibility of interventional research. RESULTS: 116). Among the interventional studies, nearly 50% studies were funded, 87.7% were randomized, and 79.4% of the primary outcome indicators were objective. However, the sample size of the studies ranged from 60 to 200, with the total sample size accounting for 40% of the confirmed infected population. More than 60% studies might face the problem of insufficient sample size. CONCLUSIONS: COVID-19 clinical study registration has been considerable, rapid, and high quality in study design. However, the feasibility of these studies may still be problematic, especially in such as insufficient sample size, poor coordination among multidisciplinary teams, and weak quality control in the research process.

Ähnliche Arbeiten